Sotera Health Co (SHC) Stock Price & Analysis
Sotera Health Co (SHC) rose 4.22% to USD 16.53 as of June 10, 2026 at 00:27 UTC, according to Nexqual real-time market data.
SHC last closed at USD 15.86; the session ranged USD 15.81–16.58 on volume of 3,576,490 shares. Market capitalization is $4.71B, with a 52-week range of USD 10.8–19.85 (NMS). Source: Nexqual, June 10, 2026 at 00:27 UTC.
Key Statistics (as of June 10, 2026 at 00:27 UTC)
| Price | USD 16.53 |
|---|---|
| Change | ▲ 4.22% (up) |
| Previous Close | USD 15.86 |
| Open | USD 16.02 |
| Day Range | USD 15.81 – 16.58 |
| 52-Week Range | USD 10.8 – 19.85 |
| Volume | 3,576,490 shares |
| Market Cap | $4.71B |
| Exchange | NMS |
Technical Analysis (SHC)
Nexqual's technical model rates SHC "BUY" based on 5 bullish and 2 bearish signals across 124 daily candles, as of June 10, 2026 at 00:27 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 64.22 (neutral) |
| vs SMA50 | Above (USD 15.49) |
| MACD | 0.11 (positive) |
Analyst Ratings (SHC)
Wall Street analysts rate SHC "Buy" based on 9 analysts, with a mean price target of USD 20.11 (range USD 16–24), per Nexqual as of June 10, 2026 at 00:27 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 9 |
| Mean Target | USD 20.11 |
| High Target | USD 24 |
| Low Target | USD 16 |
| Buy / Hold / Sell | 9 / 2 / 0 |
Earnings (SHC)
| Next Earnings Date | 2026-08-06 |
|---|---|
| EPS Estimate | USD 0.24 |
| Revenue Estimate | $309.37M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.18 vs est 0.17 ▲ beat |
| 2025-12-31 | USD 0.26 vs est 0.24 ▲ beat |
| 2025-09-30 | USD 0.26 vs est 0.22 ▲ beat |
| 2025-06-30 | USD 0.2 vs est 0.17 ▲ beat |
Source: Nexqual, June 10, 2026 at 00:27 UTC.
Financials & Fundamentals (SHC)
| Total Revenue | $1.19B |
|---|---|
| Revenue Growth (YoY) | +10.00% |
| Gross Margin | +55.26% |
| Operating Margin | +31.26% |
| Profit Margin | +9.91% |
| ROE | +22.73% |
| Debt / Equity | 364.72 |
| Current Ratio | 2.82 |
| Total Cash | $314.36M |
| Total Debt | $2.27B |
| Free Cash Flow | $144.78M |
Source: Nexqual, June 10, 2026 at 00:27 UTC.
Financial Health Score (SHC)
Nexqual rates Sotera Health Co's overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 00:27 UTC.
| Growth | Solid — Revenue +6% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 55%, operating 31% |
| Balance Sheet | Weak — $314M cash vs $2.27B debt |
| Cash Flow | Solid — FCF $145M, 12% margin |
| Efficiency | Strong — ROE 23%, ROA 8.5% |
Ownership (SHC)
| Insider Ownership | +2.36% |
|---|---|
| Institutional Ownership | +90.25% |
| Shares Outstanding | 285.17M |
| Float | 191.98M |
| Short % of Float | +7.97% |
Source: Nexqual, June 10, 2026 at 00:27 UTC.
Leadership (SHC)
Sotera Health Co is led by Alton E. Shader (age 52), CEO & Director, per Nexqual as of June 10, 2026 at 00:27 UTC.
| CEO & Director | Alton E. Shader (age 52) |
|---|---|
| Executive Chairman of the Board | Michael B. Petras (age 56) |
| Senior VP & CFO | Jonathan M. Lyons (age 47) |
| President of Sterigenics U.S., LLC | Michael P. Rutz (age 54) |
| Chief Marketing Officer | Kristin A. Gibbs |
Major Backers & Investors (SHC)
Notable institutional backers of Sotera Health Co include Darsana Capital Partners, LP, Sessa Capital IM, L.P., Sculptor Capital LP, according to Nexqual as of June 10, 2026 at 00:27 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Darsana Capital Partners, LP | 9.12% |
| Sessa Capital IM, L.P. | 8.08% |
| Sculptor Capital LP | 7.62% |
| Warburg Pincus LLC | 6.7% |
| GTCR, LLC | 4.47% |
| Sachem Head Capital Management, LP | 4.08% |
| Janus Henderson Group PLC | 3.21% |
| JANUS INVESTMENT FUND-Janus Henderson Contrarian Fund | 1.7% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 14.13% |
| BlackRock | 10.06% |
Source: Nexqual, June 10, 2026 at 00:27 UTC.
From Sotera Health Co's Latest SEC 10-K Filing (filed 2026-02-24)
Key Strengths & Strategy (as disclosed to the SEC)
- General Information We are a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry.
- Nelson Labs Customers Nelson Labs serves approximately 3,000 customers, including many leading medical device manufacturers and pharmaceutical companies.
- We provide end-to-end sterilization as well as microbiological and analytical lab testing and advisory services to help ensure that medical, pharmaceutical and food products are safe for healthcare practitioners, patients and consumers in the United States and around the world.
- We offer a globally integrated platform for our customers in the medical device, pharmaceutical, food safety, and advanced applications markets, with facilities strategically located to be convenient to our customers' manufacturing sites and distribution hubs or routes.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| MRVI | Maravai LifeSciences Holdings, | USD 5.1 | ▲ 1.59% |
| PRVA | Privia Health Group, Inc. | USD 22.17 | ▲ 2.5% |
| CERT | Certara, Inc. | USD 5.18 | ▼ 3.54% |
| SGRY | Surgery Partners, Inc. | USD 13.96 | ▲ 1.82% |
| STVN | Stevanato Group S.p.A. | USD 18.1 | ▼ 1.95% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 00:27 UTC. This page is informational and not investment advice.